1. Home
  2. YEXT vs ERAS Comparison

YEXT vs ERAS Comparison

Compare YEXT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YEXT
  • ERAS
  • Stock Information
  • Founded
  • YEXT 2006
  • ERAS 2018
  • Country
  • YEXT United States
  • ERAS United States
  • Employees
  • YEXT N/A
  • ERAS N/A
  • Industry
  • YEXT EDP Services
  • ERAS Biotechnology: Pharmaceutical Preparations
  • Sector
  • YEXT Technology
  • ERAS Health Care
  • Exchange
  • YEXT Nasdaq
  • ERAS Nasdaq
  • Market Cap
  • YEXT 823.2M
  • ERAS 723.8M
  • IPO Year
  • YEXT 2017
  • ERAS 2021
  • Fundamental
  • Price
  • YEXT $6.38
  • ERAS $2.49
  • Analyst Decision
  • YEXT Buy
  • ERAS Strong Buy
  • Analyst Count
  • YEXT 4
  • ERAS 5
  • Target Price
  • YEXT $9.00
  • ERAS $5.90
  • AVG Volume (30 Days)
  • YEXT 1.2M
  • ERAS 1.2M
  • Earning Date
  • YEXT 12-09-2024
  • ERAS 11-12-2024
  • Dividend Yield
  • YEXT N/A
  • ERAS N/A
  • EPS Growth
  • YEXT N/A
  • ERAS N/A
  • EPS
  • YEXT N/A
  • ERAS N/A
  • Revenue
  • YEXT $408,973,000.00
  • ERAS N/A
  • Revenue This Year
  • YEXT $6.09
  • ERAS N/A
  • Revenue Next Year
  • YEXT $9.97
  • ERAS N/A
  • P/E Ratio
  • YEXT N/A
  • ERAS N/A
  • Revenue Growth
  • YEXT 0.95
  • ERAS N/A
  • 52 Week Low
  • YEXT $4.29
  • ERAS $1.64
  • 52 Week High
  • YEXT $8.75
  • ERAS $3.45
  • Technical
  • Relative Strength Index (RSI)
  • YEXT 29.23
  • ERAS 38.71
  • Support Level
  • YEXT $6.39
  • ERAS $2.51
  • Resistance Level
  • YEXT $8.75
  • ERAS $2.68
  • Average True Range (ATR)
  • YEXT 0.22
  • ERAS 0.22
  • MACD
  • YEXT -0.24
  • ERAS -0.05
  • Stochastic Oscillator
  • YEXT 5.07
  • ERAS 10.00

About YEXT Yext Inc.

Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: